At the end of 2020, TrialSite asked, “Does AstraZeneca’s AZD7442 Represent the Breakthrough Treatment to Address SARS-CoV-2?” as the company took $486 million in public U.S. funding and capitalized on the intellectual property of some brilliant people at Vanderbilt University to develop a long-acting antibody targeting SARS-CoV-2. The company has conducted two large clinical trials, one to test the treatment as pre-exposure prophylaxis (PrEP) and the other as post-exposure prophylaxis (PeP). Fast forward until today, and the positive, high-level results from their PROVEN study indicate that AZD7442 evidence statistically significant reduction in the incidence of symptomatic COVID-19, meeting the trial’s endpoint. Again, this data is still preliminary and must go through the formal vetting, review, and the like. A significant potential breakthrough in the war on COVID-19, this therapeutic approach may in some cases supersede vaccination use cases.
What is AZD7442?
AstraZeneca declares that this long-acting antibody (LAAB) combination first discovered by Vanderbilt represents the first possible antibody combination, that is not a vaccine, that could possibly provide long-lasti...
Note: If you need assistance with your subscription or would like to discuss a corporate subscription for more than 10 employees please contact us or use the chat (bottom right).